{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:16:38Z","timestamp":1771010198884,"version":"3.50.1"},"publisher-location":"Chichester, UK","reference-count":99,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007784","type":"reference-entry","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T19:23:45Z","timestamp":1239823425000},"source":"Crossref","is-referenced-by-count":47,"title":["HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis"],"prefix":"10.1002","author":[{"given":"Sankar D","family":"Navaneethan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pansini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Manno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD007784-BIB1|cit1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB2|cit2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1067\/mcp.2000.105330","article-title":"Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy","volume":"67","author":"Buemi","year":"2000","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007784-BIB3|cit3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF03345126","article-title":"Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study","volume":"26","author":"Dalla Nora","year":"2003","journal-title":"Journal of Endocrinological Investigation"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB4|cit4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1056-8727(01)00140-4","article-title":"Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes","volume":"15","author":"Fried","year":"2001","journal-title":"Journal of Diabetes & its Complications"},{"key":"10.1002\/14651858.CD007784-BIB5|cit5","series-title":"41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal","first-page":"258","article-title":"Nephrotic dyslipidemia, harvest of treatment [abstract]","author":"Gheith","year":"2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784-BIB6|cit6","first-page":"100","article-title":"Study the effect of treatment of nephrotic dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract no:M182]","volume":"17","author":"Gheith","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB7|cit7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000065021","article-title":"Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome","volume":"91","author":"Gheith","year":"2002","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB8|cit8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02342442","article-title":"Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy","volume":"35","author":"Hommel","year":"1992","journal-title":"Diabetologia"},{"issue":"9374","key":"10.1002\/14651858.CD007784-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007784-BIB10|cit10","first-page":"1345","article-title":"The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group","volume":"21","author":"Imai","year":"1999","journal-title":"Clinical & Experimental Hypertension - New York"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB11|cit11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00400731","article-title":"Cholesterol-lowering therapy may retard the progression of diabetic nephropathy","volume":"38","author":"Lam","year":"1995","journal-title":"Diabetologia"},{"issue":"1","key":"10.1002\/14651858.CD007784-BIB12|cit12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.0000022805.11288.7F","article-title":"Effect of pravastatin on proteinuria in patients with well-controlled hypertension","volume":"40","author":"Lee","year":"2002","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD007784-BIB13|cit13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1523-1755.2005.00457.x","article-title":"Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptor blockers","volume":"68","author":"Lee","year":"2005","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB14|cit14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2004.10.008","article-title":"Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy)","volume":"95","author":"Lemos","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB15|cit15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/17.5.798","article-title":"Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis","volume":"17","author":"Nakamura","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB16|cit16","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.2337\/dc07-0919","article-title":"Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria","volume":"30","author":"Nellemann","year":"2007","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD007784-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/BF02374502","article-title":"Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria","volume":"36","author":"Nielsen","year":"1993","journal-title":"Diabetologia"},{"issue":"19","key":"10.1002\/14651858.CD007784-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.[see comment]","volume":"339","author":"Anonymous","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD007784-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.[see comment]","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD007784-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB22|cit22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"18","key":"10.1002\/14651858.CD007784-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD007784-BIB25|cit24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2006.11.011","article-title":"Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects","volume":"196","author":"Asselbergs","year":"2008","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB24|cit25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/01.STR.0000155731.92786.e9","article-title":"Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria","volume":"36","author":"Asselbergs","year":"2005","journal-title":"Stroke"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB26|cit26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clinthera.2006.03.012","article-title":"Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)","volume":"28","author":"Atthobari","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD007784-BIB27|cit27","first-page":"36A","article-title":"Cost-effectiveness of screening for albuminuria and subsequent treatment with an ACE-inhibitor; a pharmaco-economic analysis [abstract no: TH-FC169]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784-BIB28|cit28","first-page":"71A","article-title":"The effect of statins on urinary albumin excretion (UAE) and glomerular filtration rate (GFR): a randomized controlled trial (RCT) and observational cohort study [abstract no: F-FC151]","volume":"16","author":"Atthobari","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007784-BIB29|cit29","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","article-title":"The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.[see comment]","volume":"21","author":"Atthobari","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007784-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ndt\/gfm091","article-title":"Impact of weight change on albuminuria in the general population","volume":"22","author":"Bello","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007784-BIB31|cit31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9149(00)01042-0","article-title":"Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])","volume":"86","author":"Diercks","year":"2000","journal-title":"American Journal of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD007784-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/eurheartj\/ehi253","article-title":"Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial","volume":"26","author":"Geluk","year":"2005","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB35|cit33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2008.02.108","article-title":"Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria","volume":"102","author":"Harst","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB33|cit34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.HYP.0000244082.26293.2d","article-title":"Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients","volume":"48","author":"Wal","year":"2006","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB34|cit35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3317\/jraas.2007.029","article-title":"Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects","volume":"8","author":"Wal","year":"2007","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"7","key":"10.1002\/14651858.CD007784-BIB36|cit36","first-page":"963","article-title":"Treatment of hyperlipidaemia with simvastatin (SV) and diet, vs diet alone in idiopathic membranous nephropathy (IMN) [abstract]","volume":"9","author":"Rayner","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB37|cit37","first-page":"219","article-title":"A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone","volume":"46","author":"Rayner","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"10 (Pt 1)","key":"10.1002\/14651858.CD007784-BIB38|cit38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ajh\/4.10.868","article-title":"Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects","volume":"4","author":"Scanferla","year":"1991","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD007784-BIB39|cit39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00365590510031255","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction","volume":"39","author":"Holmberg","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007784-BIB40|cit40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00365590500329304","article-title":"Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint study","volume":"39","author":"Stegmayr","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD007784-BIB41|cit41","series-title":"38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria","first-page":"134","article-title":"Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]","author":"Stegmayr","year":"2001"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784-BIB42|cit42","first-page":"161A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]","volume":"9","author":"Stegmayr","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784-BIB43|cit43","first-page":"268A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no:A1356]","volume":"10","author":"Stegmayr","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2337\/diacare.20.12.1891","article-title":"Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment","volume":"20","author":"Tonolo","year":"1997","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB46|cit46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007784-BIB47|cit47","first-page":"437a","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007784-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"Dijk","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD007784-BIB49|cit49","first-page":"329A","article-title":"Rosuvastatin reduces high sensitivity-C reactive protein and the decline in renal function in hyperlipidemic patients with chronic kidney disease. [abstract no: SA-PO134]","volume":"15","author":"Verma","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007784-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.amjcard.2005.06.074","article-title":"Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease","volume":"96","author":"Verma","year":"2005","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB51|cit51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1081\/JDI-120039826","article-title":"Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease","volume":"26","author":"Yasuda","year":"2004","journal-title":"Renal Failure"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB52|cit52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0168-8227(95)01138-2","article-title":"Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients","volume":"29","author":"Zhang","year":"1995","journal-title":"Diabetes Research & Clinical Practice"},{"key":"10.1002\/14651858.CD007784-BIB53|cit53","unstructured":"AURORA: A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events http:\/\/www.nrr.nhs.uk\/search.htm"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB54|cit54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000106803","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study","volume":"30","author":"Fellstrom","year":"2007","journal-title":"Kidney & Blood Pressure Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007784-BIB55|cit55","first-page":"713","article-title":"A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study [abstract]","volume":"18","author":"Fellstrom","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007784-BIB56|cit56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1468-6708-6-9","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study","volume":"6","author":"Fellstrom","year":"2005","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD007784-BIB57|cit57","unstructured":"Anonymous Study of Heart and Renal Protection (SHARP) SHARP Study [http:\/\/www.ctsu.ox.ac.uk\/\u02dcsharp\/] 2003"},{"issue":"Suppl 84","key":"10.1002\/14651858.CD007784-BIB58|cit58","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"8934","key":"10.1002\/14651858.CD007784-BIB59|cit59","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Anonymous","year":"1994","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007784-BIB60|cit60","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1681\/ASN.2004110958","article-title":"Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?","volume":"16","author":"Campese","year":"2005","journal-title":"Journal of American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007784-BIB62|cit62","unstructured":"Walker R Lipid lowering therapy in patients with chronic kidney disease http:\/\/www.cari.org.au\/CKD_cardio_list_published\/Lipid%20Lowering%20Therapy.pdf"},{"issue":"17","key":"10.1002\/14651858.CD007784-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB64|cit64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD007784-BIB65|cit65","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1046\/j.1523-1755.2001.07824.x","article-title":"Role of oxidized low-density lipoprotein in the atherosclerosis of uremia","volume":"78","author":"Drueke","year":"2001","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB66|cit66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"Journal of American Society of Nephrology"},{"issue":"13","key":"10.1002\/14651858.CD007784-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB68|cit68","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/ndt\/gfi159","article-title":"ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends","volume":"20","author":"Grassmann","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB69|cit69","first-page":"263","article-title":"Assessment of the efficacy of treatment of dyslipidemia in renal outpatients","volume":"15","author":"Harris","year":"2002","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB70|cit70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","article-title":"Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials","volume":"278","author":"Hebert","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB71|cit71","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1523-1755.2002.kid571.x","article-title":"Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study","volume":"62","author":"Henry","year":"2002","journal-title":"Kidney International"},{"issue":"9374","key":"10.1002\/14651858.CD007784-BIB72|cit72","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB73|cit73","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB74|cit74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/01.RES.62.2.367","article-title":"Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5\/6 nephrectomy model of chronic renal failure","volume":"62","author":"Kasiske","year":"1988","journal-title":"Circulation Research"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD007784-BIB75|cit75","first-page":"S39","article-title":"Clinical practice guidelines for managing dyslipidemias in chronic kidney disease: III. Treating dyslipidemias","volume":"41","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD007784-BIB76|cit76","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1046\/j.1523-1755.2000.07503.x","article-title":"The role of lipids in renal disease: future challenges","volume":"75","author":"Keane","year":"2000","journal-title":"Kidney International - Supplement"},{"issue":"4A","key":"10.1002\/14651858.CD007784-BIB77|cit77","doi-asserted-by":"crossref","first-page":"9B","DOI":"10.1016\/S0002-9149(02)03268-X","article-title":"Effects of statins on inflammation in patients with acute and chronic coronary syndromes","volume":"91","author":"Kinlay","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007784-BIB78|cit78","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0149-2918(97)80102-6","article-title":"Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials","volume":"19","author":"Kong","year":"1997","journal-title":"Clinical Therapeutics"},{"issue":"7404","key":"10.1002\/14651858.CD007784-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007784-BIB80|cit80","doi-asserted-by":"crossref","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch6"},{"issue":"19","key":"10.1002\/14651858.CD007784-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007784-BIB82|cit82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"Manjunath","year":"2003","journal-title":"Journal of American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD007784-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ndt\/16.9.1738","article-title":"Statins: effects beyond cholesterol lowering","volume":"16","author":"Massy","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007784-BIB84|cit84","unstructured":"United States Cochrane Center Master list of journals being searched http:\/\/apps1.jhsph.edu\/cochrane\/masterlist.asp"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB85|cit85","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"Journal of American Society of Nephrology"},{"key":"10.1002\/14651858.CD007784-BIB86|cit86","unstructured":"The Renal Association Clinical Practice Guidelines: Module 2 - Complications of CKD http:\/\/www.renal.org\/guidelines\/module2.html#Summary-49575"},{"key":"10.1002\/14651858.CD007784-BIB87|cit87","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 1. Art. No.: RENAL"},{"issue":"10","key":"10.1002\/14651858.CD007784-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction. A Meta-Regression Analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"Journal of American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD007784-BIB89|cit89","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"Journal of American Society of Nephrology"},{"issue":"17","key":"10.1002\/14651858.CD007784-BIB90|cit90","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD007784-BIB91|cit91","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1681\/ASN.V1482084","article-title":"Cholesterol and the risk of renal dysfunction in apparently healthy men","volume":"14","author":"Schaeffner","year":"2003","journal-title":"Journal of American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD007784-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD007784-BIB93|cit93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00041552-200203000-00001","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient","volume":"11","author":"Sica","year":"2002","journal-title":"Current Opinion in Nephrology and Hypertension"},{"issue":"12","key":"10.1002\/14651858.CD007784-BIB94|cit94","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1345\/aph.10124","article-title":"Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol","volume":"34","author":"Sotiriou","year":"2000","journal-title":"Annals of Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007784-BIB95|cit95","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD007784-BIB96|cit96","unstructured":"USRDS: United States Renal Data System http:\/\/www.usrds.org\/2007\/pdf\/06_hosp_morte_07.pdf"},{"issue":"3","key":"10.1002\/14651858.CD007784-BIB97|cit97","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD007784-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"7645","key":"10.1002\/14651858.CD007784-BIB99|cit99","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","article-title":"Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials","volume":"336","author":"Strippoli","year":"2008","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007784.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,5,31]],"date-time":"2014-05-31T00:00:00Z","timestamp":1401494400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007784\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T16:52:25Z","timestamp":1710262345000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007784"}},"subtitle":[],"editor":[{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":99,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007784","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007784.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2009,4,15]]}}}